Deutsche Bank Starts Regeneron Pharma (REGN) at Hold

Deutsche Bank analyst James Shin initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Hold rating and a price target of $800.00.

The analyst comments "We're initiating coverage of REGN with a Hold rating and $800 PT based on our view that current valuations assumes that HD Eylea stabilizes the Eylea franchise with Dupixent driving growth. REGN is most well-known for its antibody engineering, particularly the creation of Eylea, which is the current Gold Standard for treating wet age-related macular degeneration (wAMD), a degenerative disease that causes vision deterioration – for generalists, we have more background on REGN, wAMD and Eylea in the Appendix (slide 33). While Retina Specialists affirm that standard, 2mg Eylea is an excellent treatment for wAMD patients, real-world feedback for Roche’s new agent – Vabysmo – has been positive and indicate it’s eating into Eylea’s market share."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $830.79 yesterday.

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• UBS Reiterates Buy Rating on HF Sinclair (DINO)